MARKET

ACST

ACST

Acasti Pharma Inc
NASDAQ
3.405
+0.005
+0.15%
After Hours: 3.280 -0.125 -3.67% 18:41 04/12 EDT
OPEN
3.340
PREV CLOSE
3.400
HIGH
3.415
LOW
3.305
VOLUME
5.89K
TURNOVER
0
52 WEEK HIGH
3.840
52 WEEK LOW
1.720
MARKET CAP
32.00M
P/E (TTM)
-0.6724
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ACST last week (0401-0405)?
Weekly Report · 6d ago
Weekly Report: what happened at ACST last week (0325-0329)?
Weekly Report · 04/01 10:19
Weekly Report: what happened at ACST last week (0318-0322)?
Weekly Report · 03/25 10:22
Weekly Report: what happened at ACST last week (0311-0315)?
Weekly Report · 03/18 10:20
Weekly Report: what happened at ACST last week (0304-0308)?
Weekly Report · 03/11 10:18
Weekly Report: what happened at ACST last week (0226-0301)?
Weekly Report · 03/04 10:20
Weekly Report: what happened at ACST last week (0219-0223)?
Weekly Report · 02/26 10:28
Weekly Report: what happened at ACST last week (0212-0216)?
Weekly Report · 02/19 10:29
More
About ACST
Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

Webull offers Acasti Pharma Inc stock information, including NASDAQ: ACST real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACST stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACST stock methods without spending real money on the virtual paper trading platform.